CAPA and Deviation Management: A Growing Compliance Risk

Quality backlogs in life sciences rarely begin with a single failure. They form as ordinary work accumulates across pharmaceutical, biotechnology, and medical device operations during periods of growth, regulatory change, increasing product complexity, or limited specialist capacity. A deviation remains open while the quality team handles a more urgent event, while a CAPA (Corrective and Preventive Action) moves past its target date because the investigation needs more data.

Each decision may be reasonable on its own, but the risk grows when unresolved deviations, CAPAs, and change controls begin to outpace the organization’s ability to close them well. The backlog then becomes a constraint on audits, production timelines, regulatory confidence, and team capacity.

How Quality Backlogs Become an Operational Constraint

Quality backlogs often remain manageable for longer than expected because life sciences teams keep operating around them. Review meetings increase, target dates move, and experienced quality specialists are redirected toward older investigations. Those steps may protect immediate priorities, but they reduce the capacity available for current deviations, CAPAs, change controls, and release activities.

The pressure then compounds. New quality events enter a system already carrying overdue investigations, while manufacturing changes, validation work, and product decisions wait for related records to close. Pharmaceutical, biotechnology, and medical device organizations may still be moving products and programs forward, yet more of their operating capacity is being absorbed by unfinished quality work.

FDA’s Quality Management Maturity program reflects the value of reliable performance and continual improvement across pharmaceutical operations. When unresolved work becomes normal, the quality system has less room to detect patterns early, prevent repeat problems, and maintain consistent inspection readiness.

When Unresolved Quality Work Begins to Slow the Business 

A growing backlog changes more than a dashboard. It affects how quickly teams can prepare records, answer questions, and make decisions across the operation.

Common effects include:

• Longer audit preparation because records need additional review or explanation.
• Reduced capacity as specialists reopen investigations or resolve missing information.
• Slower production and change timelines when approvals depend on overdue work.
• Weaker inspection readiness because timely investigation and follow-through are harder to demonstrate.
• Greater regulatory exposure when repeat issues show that earlier actions were ineffective.

The FDA considers quality deviations, corrective actions, facility history, and potential patient harm when assessing pharmaceutical compliance. Warning Letter closeout also depends on corrective actions being completed and verified, often through a follow-up inspection.

A backlog can therefore shape both the immediate response and the organization’s ability to prove that control has been restored.

Data Traceability Weakens Across Quality and Evidence Systems

The impact can also reach evidence generation when teams need to connect quality events with safety, post-market, or product performance records. Real-world evidence depends on reliable real-world data, and gaps in data traceability can make RWE and RWD analyses harder to interpret or defend.

Incomplete investigations and poorly documented changes create uncertainty about what happened, when it happened, and which products or processes were affected. FDA guidance on data integrity reinforces the need for regulated data to remain reliable, accurate, complete, and supported by risk-based controls.

What a Global CDMO Faced When the Backlog Took Hold

For one leading global contract development and manufacturing organization, the backlog was exposing production timelines, client trust, and regulatory approval. An FDA Warning Letter cited more than 2,000 unresolved deviations across its US facilities, creating a remediation challenge that temporary staffing alone could not solve.

Reducing the volume was essential, but closing records without improving the investigation model would only create a short-lived recovery. The organization also needed stronger governance, more consistent root-cause analysis, and a clear way to transfer knowledge back to its internal team.

How Raland Built a Sustainable Quality Remediation Model

Raland, an Akkodis specialty brand, provided regulatory expertise and delivery support to help reduce the organization’s backlog during a pending acquisition. Consultants brought practical knowledge of how investigation quality, CAPA effectiveness, and management oversight are assessed during inspections, while Akkodis provided the delivery scale needed to mobilize a large team under one governance structure.

The immediate focus was reducing the volume of unresolved records within the site. Through its work on deviations and related CAPAs, the Raland team also contributed to the organization’s broader process-improvement efforts.

Key elements included:

• Unified governance across the remediation team.
• Risk-based triage for deviations and related CAPAs.
• Consistent investigation and root-cause standards.
• Clear review, escalation, and approval paths.
• Training and knowledge transfer for the client’s quality organization.

Why the Results Point to Lasting Quality Recovery

More than 40 QA specialists were deployed within four weeks, although mobilization speed was only the start. Over the 18-month engagement, the backlog fell from more than 2,000 deviations to fewer than 100, bringing the remaining workload within a range the client’s team could manage.

The engagement also demonstrated the value of the team’s investigation capabilities. At the close of the project, the client hired the remaining Raland specialists to continue supporting the efficient closure of robust investigations.

Reducing the backlog helped the client regain control of unresolved records and established a stronger foundation for remediation. Knowledge transfer and training helped the client sustain the newly improved investigation practices.

Backlog Management as an Operating Discipline

Quality backlogs become business risk when unresolved work is treated as something to address periodically rather than as a continuous operating signal. A risk-based approach makes the workload visible earlier, protects capacity for the highest-impact items, and creates accountability before overdue records begin constraining production or inspection readiness.

Stronger quality organizations track aging, recurrence, root-cause quality, effectiveness checks, and resource demand as connected indicators of system health. They also test whether investigation and CAPA processes are sustainable before a regulatory event forces the issue. 

Our team supports life sciences organizations as they strengthen quality operations, restore inspection readiness, and build remediation models that remain effective after the immediate backlog is reduced. Unresolved work remains a defining constraint until backlog management becomes part of how the quality system operates every day.

Is your team looking to reduce quality backlogs while building a more sustainable operating model? Contact our experts today to discuss the right level of support.